[pubmed] The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwis

Intégration des publications parues sur PUBMED
Avatar du membre

Auteur du sujet
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 310
Enregistré le : 31 mai 2020 09:57
    Linux Chrome
Zodiaque :
Âge : 20

[pubmed] The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwis

Message par RSS-Bot »

Biomedicines. 2020 Sep 16;8(9):E355. doi: 10.3390/biomedicines8090355.


This manuscript presents quantitative findings on the actual effectiveness of terminal complement component 5 (C5) inhibitors and complement component 1 (C1) esterase inhibitors through their formal and common "off-label" (compassionate) indications. The results emanated from pairwise and network meta-analyses to present evidence until September 2019. Clinical trials (CT) and real-life non-randomized studies of the effects of interventions (NRSI) are consistent on the benefits of C5 inhibitors and of the absence of effects of C1 esterase inhibitors (n = 7484): Mathematically, eculizumab (surface under the cumulative ranking area (SUCRA) >0.6) and ravulizumab (SUCRA ≥ 0.7) were similar in terms of their protective effect on hemolysis in paroxysmal nocturnal hemoglobinuria (PNH), thrombotic microangiopathy (TMA) in atypical hemolytic uremic syndrome (aHUS), and acute kidney injury (AKI) in aHUS, in comparison to pre-/off-treatment state and/or placebo (SUCRA < 0.01), and eculizumab was efficacious on thrombotic events in PNH (odds ratio (OR)/95% confidence interval (95% CI) in CT and real-life NRSI, 0.07/0.03 to 0.19, 0.24/0.17 to 0.33) and chronic kidney disease (CKD) occurrence/progression in PNH (0.31/0.10 to 0.97, 0.66/0.44 to 0.98). In addition, meta-analysis on clinical trials shows that eculizumab mitigates a refractory generalized myasthenia gravis (rgMG) crisis (0.29/0.13 to 0.61) and prevents new acute antibody-mediated rejection (AMR) episodes in kidney transplant recipients (0.25/0.13 to 0.49). The update of findings from this meta-analysis will be useful to promote a better use of complement inhibitors, and to achieve personalization of treatments with this class of drugs.

PMID:32948059 | DOI:10.3390/biomedicines8090355

Source: https://pubmed.ncbi.nlm.nih.gov/3294805 ... 7&v=2.11.5
Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com

Nous prenons en charge le coût de cette demande (en général +/- USD 40,00$) dans la limite de nos ressources.

Bonne lecture...

Retourner vers « Echos de la recherche »